hVIVO (OPORF) EPS (Basic) : $0.03 (TTM As of Jun. 2024)

View and export this data going back to 2020. Start your Free Trial

What is hVIVO EPS (Basic)?

hVIVO's basic earnings per share (Basic EPS) for the six months ended in Jun. 2024 was $0.01. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Jun. 2024 was $0.03.

hVIVO's EPS (Diluted) for the six months ended in Jun. 2024 was $0.01. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was $0.03.

hVIVO's EPS without NRI for the six months ended in Jun. 2024 was $0.01. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Jun. 2024 was 0.02.

During the past 12 months, hVIVO's average EPS without NRIGrowth Rate was -6.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, hVIVO's highest 3-Year average EPS without NRI Growth Rate was 61.10% per year. The lowest was -47.70% per year. And the median was 14.75% per year.

hVIVO EPS (Basic) Historical Data

The historical data trend for hVIVO's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

hVIVO EPS (Basic) Chart

hVIVO Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EPS (Basic)

Get a 7-Day Free Trial

-0.05

-0.02

0.03

hVIVO Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
EPS (Basic)	Get a 7-Day Free Trial															-	-	0.01	0.02	0.01

hVIVO EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

hVIVO's Basic EPS for the fiscal year that ended in Dec. 2023 is calculated as

Basic EPS (A: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(20.399	-	0)	/	677.444
	=	0.03

hVIVO's Basic EPS for the quarter that ended in Jun. 2024 is calculated as

Basic EPS (Q: Jun. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(6.69	-	0)	/	680.372
	=	0.01

EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.03

hVIVO (OTCPK:OPORF) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

hVIVO EPS (Basic) Related Terms

Thank you for viewing the detailed overview of hVIVO's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

hVIVO Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » hVIVO PLC (OTCPK:OPORF) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

ORPH:UK HVO:UK CRO:Germany

Address

42, New Road, Queen Mary Bioenterprises Innovation Centre, London, GBR, E1 2AX

Website

https://www.hvivo.com

hVIVO PLC is a European-focused, rare, and orphan drug consulting services platform. The principal activity of the Group is that of a rapidly growing specialist CRO pharmaceutical services company, which involves the testing of vaccines and antivirals using human-challenge clinical trials. The group is also engaged in Venn Life Sciences' Clinical Research Division, providing a suite of consulting and clinical trial services to pharmaceutical, biotechnology, and medical device organizations.

hVIVO Headlines

From GuruFocus

Half Year 2024 hVIVO PLC Investor Presentation Transcript

By GuruFocus Research • 09-11-2024

Open Orphan plc Announces �3m COVID-19 Challenge Virus Manufacturing Contract

By Business Wire Business Wire • 05-10-2021

Ethics Approval Granted for Open Orphan's COVID-19 Human Challenge Study Model

By Business Wire Business Wire • 02-17-2021

Half Year 2023 hVIVO PLC Earnings Call Transcript

By GuruFocus Research • 02-14-2024

Full Year 2023 hVIVO PLC Analyst Briefing Transcript

By GuruFocus Research • 04-12-2024